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Abstract Discrete-choice experiments (DCEs) have be-
come a commonly used instrument in health economics
and patient-preference analysis, addressing a wide range of
policy questions. An important question when setting up a
DCE is the size of the sample needed to answer the re-
search question of interest. Although theory exists as to the
calculation of sample size requirements for stated choice
data, it does not address the issue of minimum sample size
requirements in terms of the statistical power of hypothesis
tests on the estimated coefficients. The purpose of this
paper is threefold: (1) to provide insight into whether and
how researchers have dealt with sample size calculations
for healthcare-related DCE studies; (2) to introduce and
explain the required sample size for parameter estimates in
DCEs; and (3) to provide a step-by-step guide for the
calculation of the minimum sample size requirements for
DCEs in health care.
Key Points for Decision Makers
The minimum sample size needed for a discrete-
choice experiment (DCE) depends on the specific
hypotheses to be tested.
DCE practitioners should realize that a small size
effect may still be meaningful, but that a limited
sample size prevents detection of such small effects.
Policy makers should not make a decision on non-
significant outcomes without considering whether
the study had a reasonable power to detect the
anticipated outcome.
1 Introduction
Discrete-choice experiments (DCEs) have become a com-
monly used instrument in health economics and patient-
preference analysis, addressing a wide range of policy
questions [1, 2]. DCEs allow for a quantitative elicitation
of individuals’ preferences for health care interventions,
services, or policies. The DCE approach combines con-
sumer theory [3], random utility theory [4], experimental
design theory [5], and econometric analysis [1]. See Lou-
viere et al. [6], Hensher et al. [7], Rose and Bliemer [8],
Lancsar and Louviere [9], and Ryan et al. [10] for further
details on conducting a DCE.
DCE-based research in health care is often concerned
about establishing the impact of certain healthcare inter-
ventions and aspects (i.e., attributes) thereof on patients’
decisions [11–20]. Consequently, a typical research
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question is to establish whether or not individuals are in-
different between two attribute levels. For instance: Do
patients prefer delivery at home more than in a hospital?;
Do patients prefer a medical specialist over an nurse
practitioner?; Do patients prefer every 5 year screening
over every 10 year screening?; Do patients prefer a weekly
oral medication over a monthly injection?; Do patients
prefer the explanation of their medical results through a
face-to-face contact more than through a letter? As a result,
an important design question is the size of the sample
needed to answer such a research question. When consid-
ering the required sample size, DCE practitioners need to
be confident that they have sufficient statistical power to
detect a difference in preferences when this difference is
sufficiently large. A practical solution (that does not require
any sample size calculations) is to simply maximize the
sample size given the research budget at hand, i.e., trying to
overpower the study as much as possible. This is beneficial
for reasons other than statistical precision (e.g. to facilitate
in-depth analysis). However, particularly in the health care
area, the number of eligible patients and healthcare pro-
fessionals is generally limited. Although theory exists as to
the calculation of sample size requirements for stated
choice data, it does not address the issue of minimum
sample size requirements in terms of testing for specific
hypotheses based on the parameter estimates produced
[21].
The purpose of this paper is threefold. The first objective
is to provide insight into whether and how researchers have
dealt with sample size calculations for health care-related
DCE studies. The second objective is to introduce and
explain the required sample size for parameter estimates in
DCEs. The final objective of this manuscript is to provide a
step-by-step guide for the calculation of the minimum
sample size requirements for DCEs in healthcare.
2 Literature Review
2.1 Methods
To gain insight into the current approaches to sample size
determination, we reviewed health care-related DCE
studies published in 2012. Older literature was ignored, as
the research frontier for methodological issues has shifted a
lot over the past years [1, 22]. MEDLINE was used to
identify healthcare-related DCE studies, replicating the
methodology of two comprehensive reviews of the
healthcare DCE literature [1, 2]. The following search
terms were used: conjoint, conjoint analysis, conjoint
measurement, conjoint studies, conjoint choice experiment,
part-worth utilities, functional measurement, paired com-
parisons, pairwise choices, discrete choice experiment, dce,
discrete choice mode(l)ling, discrete choice conjoint ex-
periment, and stated preference. Studies were included if
they were choice-based, published as a full-text English
language article, and applied to healthcare. Consideration
was given to background information of the studies, and
detailed consideration was given to whether and how
sample size calculations were conducted. We also briefly
describe the methods that have been used to obtain sample
size estimates so far.
2.2 Literature Review Results
The search generated 505 possible references. After read-
ing abstracts or full articles, 69 references met the inclusion
criteria. The appendix shows the full list of references
[Electronic Supplementary Material (ESM) 1]. Table 1
summarizes the review data. Most DCE studies were from
the UK, with the USA, Canada, and Australia also major
contributors. Studies having 4–6 attributes and 9–16 choice
sets per respondent were commonly used in the published
healthcare-related DCE studies in 2012. The sample sizes
differed substantially between the DCE studies.
Of 69 DCEs, 22 (32 %) had sample sizes smaller than
100 respondents, whereas 16 (23 %) of the 69 DCEs had
sample sizes larger than 600 respondents; six (9 %)
DCEs even had sample sizes larger than 1000 respon-
dents. More than 70 % of the DCE studies (49 of 69)
did not (clearly) report whether and what kind of sample
size method was used; 12 % of the studies (8 of 69) just
referred to other DCE studies to explain the sample size
used. For example, Huicho et al. [23] mentioned that
‘‘Based on the experience of previous studies [24, 25],
we aimed for a sample size of 80 nurses and midwives’’,
and Bridges et al. [26] mentioned ‘‘In a previously
published pilot study, the conjoint analysis approach was
shown to be both feasible and functional in a very low
sample size (n = 20) [27]’’. In 13 % of the DCE studies
(9 of 69 [28–36]), one or more of the following rules of
thumb were used to estimate the minimum sample size
required: that proposed by (1) Johnson and Orme [37,
38]; (2) Pearmain et al. [39]; and/or (3) Lancsar and
Louviere [9].
In short, the rule of thumb as proposed by Johnson and
Orme [37, 38] suggests that the sample size required for the
main effects depends on the number of choice tasks (t), the
number of alternatives (a), and the number of analysis cells
(c) according to the following equation:
N[ 500c=ðt  aÞ ð1Þ
When considering main effects, ‘c’ is equal to the
largest number of levels for any of the attributes. When
considering all two-way interactions, ‘c’ is equal to the
largest product of levels of any two attributes [38].
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The rule of thumb proposed by Pearmain et al. [39]
suggests that, for DCE designs, sample sizes over 100 are
able to provide a basis for modeling preference data,
whereas Lancsar and Louviere [9] mentioned ‘‘our em-
pirical experience is that one rarely requires more than 20
respondents per questionnaire version to estimate reliable
models, but undertaking significant post hoc analysis to
identify and estimate co-variate effects invariably requires
larger sample size’’.
Four of 69 (6 %) reviewed DCE studies used a para-
metric approach to estimate the minimum sample size re-
quired (a parametric approach can be used if one assumes,
for example based on the law of large numbers, that the
focal quantity—an estimated probability or coefficient—is
Normally distributed. This assumption facilitates the
derivation of the minimum sample sizes required). That is,
three studies used the parametric approach as proposed by
Louviere et al. [6] and one study [40] reported the para-
metric approach as proposed by Rose and Bliemer [21].
Louviere et al. [6] assume the study is being conducted to
measure a choice probability with some desired level of
accuracy. The asymptotic sampling distribution (i.e., the
distribution as sample size N ? ?) of a proportion pN,
obtained by a random sample of size N, is Normal with
mean p (the true population proportion) and variance pq/N,
where q = 1-p. The minimum sample size to estimate the
true proportion within a1 % of the true value p with a
probability a2 or greater has to satisfy the requirement that
Prob(|pN-p| B a1p) C a2, which can be calculated using
the following equation:
N[ ðq=ðrpa21ÞÞ  U1ð1
a2
2
Þ
 2
ð2Þ
where U-1 is the inverse cumulative Normal distribution
function, and r is the number of choice sets per respondent.
Hence, the parametric approach as proposed by Louviere
et al. [6] suggests that the sample size required for the main
effects depends on the number of choice sets per respon-
dent (r), the true population proportion (p), the one minus
true population proportion (q), the inverse cumulative
Normal distribution function (U-1), the allowed deviation
from the true population proportion (a1), and the sig-
nificance level (a2).
The parametric approach that has been recently intro-
duced by Rose and Bliemer [21] focuses on the minimum
sample size required based on the most critical parameter
(i.e., to be able to determine whether each parameter value
is statistically significant from zero). This parametric ap-
proach can only be used if prior parameter estimates are
available and not equal to zero. The minimum required
sample size to state with 95 % certainty that a parameter
estimate is different from zero can be determined according
to the following equation:
N[ max
k
ð1:96
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃX
ck
=
q
ckÞ2 ð3Þ
where ck is the parameter estimate of attribute k, and Rck is
the corresponding variance of the parameter estimate of
attribute k.
Table 1 Background information and sample size (method) used of
published health care-related discrete-choice experiment studies in
2012 (N = 69)
Item N (%)
Country of origina
UK 16 (23)
USA 13 (19)
Canada 10 (14)
Australia 7 (10)
Germany 6 (9)
Netherlands 4 (6)
Denmark 3 (4)
Other 19 (28)
Number of attributesa
2–3 5 (7)
4–5 24 (35)
6 25 (36)
7–9 17 (25)
[9 3 (4)
Number of choices per respondent
8 or fewer 14 (20)
9–16 choices 47 (68)
More than 16 choices 5 (7)
Not clearly reported 3 (4)
Sample size useda
\100 22 (32)
100–300 28 (41)
300–600 17 (25)
600–1,000 10 (14)
[1,000 6 (9)
Sample size method useda
Parametric approach 4 (6)
Louviere et al. [6] 3 (4)
Rose and Bliemer [21] 1 (1)
Rule of thumb 9 (13)
Johnson and Orme [28, 29] 5 (7)
Pearmain et al. [30] 2 (3)
Lancsar and Louviere [9] 3 (4)
Referring to studies 8 (12)
Review studies 3 (4)
Applied studies 5 (7)
Not (clearly) reported 49 (71)
a Totals do not add up to 100 % as some studies were conducted in
different countries, used a different number of attributes per discrete-
choice experiment, used several subgroups of respondents, and/or
used multiple sample size methods
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2.3 Comment on the State of Play
The disadvantage of using one of the rules of thumb
mentioned in paragraph 2.2 is that such rules are not
intended to be strictly accurate or reliable. The para-
metric approach as proposed by Louviere et al. [6] is not
suitable for determining the minimum required sample
size for coefficients in DCEs, as this approach focuses on
choice probabilities and does not address the issue of
minimum sample size requirements in terms of testing for
specific hypotheses based on the parameter estimates
produced. The parametric approach for minimum sample
size calculation proposed by Rose and Bliemer [21] is
solely based on the most critical parameter, so it is not
specific to a certain hypothesis. It also does not depend
on a desired power level for the hypothesis tests of
interest.
3 Determining Required Sample Sizes for Discrete-
Choice Experiments (DCEs): Theory
In this section we explain the analysis needed to deter-
mine the minimum sample size requirements in terms of
testing for specific hypotheses for coefficients in DCEs.
Our proposed approach is more general than the para-
metric approaches mentioned in Sect. 2, as it can be used
for any particular hypothesis that is relevant to the re-
searcher. We outline which elements are required before
such a minimum sample size can be determined, why
these elements are needed, and how to calculate the re-
quired sample size. To provide a step-by-step guide that
is useful for researchers from all different kinds of
backgrounds, we strive to keep the number of formulas in
this section as low as possible. Nevertheless, a compre-
hensive explanation of the minimum sample size calcu-
lation for coefficients in DCEs can be found in the
appendix (ESM 2).
3.1 Required Elements for Estimating Minimum
Sample Size
Before the minimum sample size for coefficients in a DCE
can be calculated, the following five elements are needed:
• Significance level (a)
• Statistical power level (1-b)
• Statistical model used in the DCE analysis [e.g.,
multinomial logit (MNL) model, mixed logit (MIXL)
model, generalized multinomial logit (G-MNL) model]
• Initial belief about the parameter values
• The DCE design.
3.1.1 Significance Level (a)
The significance level a sets the probability for an incorrect
rejection of a true null hypothesis. For example, if one
wants to be 95 % confident that the null hypothesis will
not be rejected when it is true, a needs to be set at
1-0.95 = 0.05 (i.e. 5 %). Conversely, if one decides to
perform a hypothesis test at a 1-a confidence level, there
is by definition an a probability of finding a significant
deviation when there is in fact no true effect. Perhaps un-
surprisingly, the smaller the imposed value of a (i.e., the
more certainty one requires), the larger the minimum re-
quired sample size will be.
3.1.2 Statistical Power Level (1-b)
b indicates the probability of failing to reject a null hy-
pothesis when the null hypothesis is actually false. The
chosen value of beta is related to the statistical power of a
test (which is defined as 1-b). As we want to assess
whether a parameter value (coefficient) is significantly
different from zero, we can define the sample size that
enables us to find a significant deviation from zero in at
least (1-b) 9 100 % of the cases. For example, a statis-
tical power of 0.8 (or 80 %) means that a study (when
conducted repeatedly over time) is likely to produce a
statistically significant result eight times out of ten. A
larger statistical power level will increase the minimum
sample size needed.
3.1.3 Statistical Model Used in the DCE Analysis
The calculation of the minimum required sample size also
depends on the type of statistical model that will be used to
analyze the DCE data (e.g., MNL, MIXL, G-MNL). The
type of statistical model affects the number of parameters
that needs to be estimated, the corresponding parameter
values, and the parameter interpretation. As a consequence,
the estimation precision of the parameters, which we will
characterize through the variance covariance matrix of the
estimated parameters, also depends on the statistical model
that is used. In order to properly determine the estimation
precision of each of the parameters, the statistical model
needs to be specified.
3.1.4 Initial Belief About the Parameter Values
Of course, if the true values of the parameters (coefficients)
were known, one would not need to execute the DCE.
Nevertheless, before a minimum sample size can be de-
termined, an initial estimate of the parameter values is
required for two reasons. First, in models that are nonlinear
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in the parameters, such as choice models, the asymptotic
variance–covariance matrix (AVC) depends on the values
of the parameters themselves. This AVC is an intermediate
stage in the sample size calculation (see Sect. 3.2 for more
details), and reflects the expected accuracy of the statistical
estimates obtained using the statistical model as identified
under Sect. 3.1.3. Second, before a power calculation can
be done, one has to describe a specific hypothesis and the
power one wants to achieve given a certain degree of
misspecification (i.e., the degree to which the true coeffi-
cient value deviates from its hypothesized value). As null
hypothesis, we will use the hypothesis that there is no in-
fluence so the coefficient equals zero. The initial estimate
of the parameter value can then be used as value for the
effect size. The closer to zero the effect size is, the more
difficult it will be to find a significant effect and hence the
larger the minimum sample size will be. To obtain some
insight into these parameter values, a small pilot DCE
study—for example with 20–40 respondents—may be
helpful.
3.1.5 DCE Design
The large literature on efficient design generation indicates
the importance of the design in getting accurate estimates
and powerful tests. The DCE design is described by the
number of choice sets, the number of alternatives per
choice set, the number of attributes, and the combination of
the attribute levels in each choice set. The DCE design has
a direct influence on the AVC, which affects the estimation
precision of the parameters, and hence will have a direct
influence on the minimum sample size required.1
3.2 Sample Size Calculation for DCEs
Once all five required elements mentioned in Sect. 3.1 have
been determined, the minimum required sample size for the
estimated coefficients in a DCE can be calculated. First, as
an intermediate part of the sample size calculation, the
AVC has to be established. That is, the statistical model
(Sect. 3.1.3), the initial belief on the parameter values,
denoted with c (Sect. 3.1.4), and the DCE design (Sect.
3.1.5), are all needed to infer the AVC matrix,
P
c, of the
estimated parameters. Details on how to construct the
variance–covariance matrix from this information can be
found, for example, in McFadden [4] for MNL and in
Bliemer and Rose [41] for panel MIXL. A variance–co-
variance matrix is a square matrix that contains the vari-
ances and covariances associated with all the estimated
coefficients. The diagonal elements of this matrix contain
the variances of the estimated coefficients, and the off-
diagonal elements capture the covariances between all
possible pairs of coefficients. For hypothesis tests on in-
dividual coefficients, we only need the diagonal elements
of
P
c, which we denote by Rck for the kth diagonal
element.
Once the AVC,
P
c, of the estimated parameters has
been established and the confidence level (a), the power
level (1-b), and the effect sizes (d) are set, the minimum
required sample size (N) for the estimated coefficients in a
DCE can be calculated (see Eq. 4).
N[ ððz1b þ z1aÞ
ﬃﬃﬃﬃﬃﬃﬃX
ck
s
=dÞ2 ð4Þ
Each of the elements in this sample size calculation
intuitively makes sense. In particular, with a larger effect
size d, a smaller sample size (N) will suffice to have
enough power to find a significant deviation. Testing at a
higher confidence level a increases z1-a,
2 and thus
increases the minimum required sample size (N). The
same holds when more statistical power is desired, as this
increases z1-b.
3 When the variance-covariance matrix
contains smaller variance (
P
ck) the minimum sample
size (N) required decreases, as the estimates will be more
precise. Smaller values for
P
ck can be obtained from using
more choice sets, more alternatives per choice set or a more
efficient design.
4 Determining Required Sample Sizes for DCEs:
A Practical Example
In this section, a practical example is provided to explain,
step-by-step, how the minimum sample size requirement
1 All aspects of our sample size calculation are conditional on the
design of the experiment and the implementation in a questionnaire.
The survey design will have an impact on the precision of the
parameters that should be accounted for through its effect on the
anticipated parameter values. Also, the model specification has an
impact on the precision of the parameters.
2 The value of a (Sect. 3.1.1) is used to determine the corresponding
quantile of the Normal distribution (z1-a) that is needed in the sample
size calculations. The value of z1-a for a given a can be found in the
basic statistics textbooks or easily calculated in Microsoft Excel
using the formula NORMSINV(1-a). The value of z1-a for an a of
0.05 equals 1.64.
3 In the computation of the sample size, we need z1-b, the quantile of
the Normal distribution with U(z1-b) = 1-b. Here again, U denotes
the cumulative distribution function of the Normal distribution.
Accordingly, the value for z1–b for a given 1–b can be found in the
basic statistics textbooks or easily calculated in Microsoft Excel
using the formula NORMSINV(1-b); e.g., assuming a statistical
power level of 80 %, the value z1-b is 0.84 [i.e., NORMSINV(0.8)].
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for a DCE study can be calculated. This is illustrated using
R-code, which can also be found at http://www.erim.eur.nl/
ecmc.
The DCE study used for this illustration concerns a DCE
about patients’ preferences for preventive osteoporosis
drug treatment [12]. In this DCE study, patients had to
choose between drug treatment alternatives that differed in
five treatment attributes: route of drug administration, ef-
fectiveness, side effects (nausea), treatment duration, and
out-of-pocket costs. The DCE design was orthogonal and
contained 16 choice sets. Each choice set consisted of two
unlabeled drug treatment alternatives and an opt-out
option.
In what follows, we show in seven steps how the
minimum sample size for coefficients can be calculated for
the DCE on patients’ preferences for preventive osteo-
porosis drug treatment.
Step 1 Significance Level (a)
We first have to set the confidence through a. In
the illustration, we choose a = 0.05. The resulting
confidence level is 95 %, assuming a one-tailed
test4 (Box 1)
Box 1
test_alpha=0.05
z_one_minus_alpha<-qnorm(1-test_alpha)
Table 2 Alternatives, attributes and levels for preventive osteoporosis drug treatment, their parameter labels, initial belief about parameter
values, and discrete-choice experiment design codes (based on de Bekker-Grob et al. [12])
Parameter label Initial belief
parameter value
DCE design
code
Alternative Alternative label
Constant (i.e., alternative specific constant for drug treatment; intercept) A 1.23
Alternative 1 Drug treatment alternative I 1
Alternative 2 Drug treatment alternative II 1
Alternative 3 Opt-out alternative 0
Attribute Attribute levels
Drug administration Tablet once a month
Tablet once a week B1 –0.31 1
Injection every 4 months B2 –0.21 1
Injection once a month B3 –0.44 1
Effectiveness ( %) C 0.028
5 5
10 10
25 25
50 50
Side effect nausea D –1.10
No 0
Yes 1
Treatment duration (years) E –0.04
1 1
2 2
5 5
10 10
Cost (€) F –0.0015
0 0
120 120
240 240
720 720
4 A one-tailed test is used if only deviations in one direction are
considered possible; in contrast, a two-tailed test is used if deviations
of the estimated parameter in either direction from zero are
considered theoretically possible. Be aware that, for a two-tailed
test, the alpha level should be divided by 2 (i.e., a/2).
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Step 2 Statistical Power Level (1-b)
The second step is to choose the statistical power
level. For our illustration, we opt for a standard
statistical power level of 80 % (i.e., b = 0.20,
hence 1-b = 0.80) (Box 2).
Step 3 Statistical Model Used in the DCE Analysis
The third step is to choose the statistical model to
analyze the DCE data. For our illustration, we opt
for an MNL model. In the R code, this affects the
way the AVC needs to be calculated, which is
outlined in step 6
Step 4 Initial Belief About the Parameter Values
The fourth step concerns the initial beliefs about the
parameter values. The DCE illustration regarding
patients’ preferences for preventive osteoporosis
drug treatment contains five attributes (two catego-
rical attributes and three linear attributes) [12],
resulting in eight parameters to be estimated (see
Table 2 column ‘parameter label’). We use the
point estimates of the parameters as our guess of the
coefficients and the effect sizes d (see Table 2
column ‘initial belief parameter value’) (Box 3)
Step 5 The DCE design
The fifth step focuses on the DCE design. The
DCE design requires eight parameters to be
estimated (ncoefficients = 8). Each choice set
contains three alternatives (nalts = 3); that is, two
drug treatment alternatives, and one opt-out
alternative. The DCE design contains 16 choice
sets (nchoices = 16) (Box 4)
The DCE design should be coded in a text-file
in such a way that it can be read correctly into
R. That is, the DCE design should contain one
row for each alternative. So, there should be
nalts 9 nchoices rows (see Table 3 as an
example for our illustration, which contains
48 rows (i.e., 3 alternatives 9 16 choice sets);
rows 1–3 correspond to choice set 1, rows 4–6
correspond to choice set 2, etc.)
Each row should contain the coded attribute
levels for that alternative. See Table 3 for how
the DCE design for our illustration was coded
(columns A–F). For example, row 1 corre-
sponds to the first preventive drug treatment
alternative in choice set 1: a drug treatment
alternative (value 1, column A) that should be
taken as a tablet every week (value 1, column
B1), which will result in a 5 % reduction of a
hip fracture (value 5, column C) without side
effects (value 0, column D), for which the drug
treatment duration will be 10 years (value 10,
column E) and out-of-pocket costs of €120 are
required (value 120, column F). Be aware that
only the DCE design (i.e., the ‘white part’ of
Table 3) should be in a text file, so that it can be
read correctly in R (Box 5)
Box 5# load the design informaon
design<-as.matrix(read.table(“….ﬁll in the ﬁle name 
of the DCE design…”,header=FALSE));
Box 2
test_beta=0.20
z_one_minus_beta<-qnorm(1-test_beta)
Box 3
parameters<-c(1.23 , -0.31 , -0.21 , -0.44 , 0.028 , 
-1.10 , -0.04 , -0.0015)
Box 4
ncoeﬃcients=8
nalts=3
nchoices=16
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Step 6 Estimation Accuracy
Having our statistical model, our initial beliefs
about the parameter values (i.e., our guess of the
effect sizes) and our DCE design matrix, we are
able to compute the AVC matrix (
P
c) (Box 6)
Step 7 Sample Size Calculation
The final step is to calculate the required sample
size for the MNL coefficients in our DCE. Hereto
we use Eq. 4 (Box 7)
The results of the minimum sample size
required to obtain the desired power level for
finding an effect when testing at a specific
confidence level for each parameter are shown
in Table 4. To illustrate the impact of the
probability that we will find a significant effect
given a specific effect size, we also computed
the required sample size for the statistical
power level 1-b equal to 0.6, 0.7, and 0.9.
Additionally, we also computed the required
Box 6
#compute the informaon matrix, see Appendix (Electronic Supplementary Material 2) for more details
# inialize a matrix of size ncoeﬃcients by ncoeﬃcients ﬁlled with zeros.
info_mat=matrix(rep(0,ncoeﬃcients* ncoeﬃcients), ncoeﬃcients, ncoeﬃcients)
# compute exp(design matrix mes inial parameter values)
expulies=exp(design%*%parameters)
# loop over all choice sets
for (k_set in 1:nchoices) {
# select alternaves in the choice set
alternaves=((k_set-1)*nalts+1) : (k_set*nalts)
# obtain vector of choice shares within the choice set
p_set=expulies[alternaves]/sum(expulies[alternaves])
# also put these probabilies on the diagonal of a matrix that only contains zeros
p_diag=diag(p_set)
# compute middle term P-pp’ in equaon A.1 of Electronic Supplementary Material 2
middle_term<-p_diag-p_set%o%p_set
# pre- and postmulply with the Xs from the design matrix for the alternaves in this choice set
full_term<-t(design[alternaves,])%*%middle_term%*%design[alternaves,]
# Add contribuon of this choice set to the informaon matrix
info_mat<-info_mat+full_term
} # end of loop over choice sets
#get the inverse of the informaon matrix (i.e., gets the variance-covariance matrix)
sigma_beta<-solve(info_mat,diag(ncoeﬃcients)) 
Box 7
# Use the parameter values as eﬀect size. Other values can be used here.
eﬀectsize<-parameters 
# formula for sample size calculaon is n>[(z_(beta)+z_(1-alpha))*sqrt(Σγκ)/delta]^2
N<-((z_one_minus_beta + z_one_minus_alpha)*sqrt(diag(sigma_beta))/abs(eﬀectsize))^2
# Display results
“required sample size for each coeﬃcient”
N
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sample sizes assuming a significance level a of
0.1, 0.025, and 0.01
As can be seen from Table 4, one needs a
minimum sample size of 190 respondents with
a statistical power of 0.8 and assuming an
a = 0.05, whether ‘injection every 4 months’ is
significantly different from ‘tablet once a
month (reference attribute level)’ (Table 4,
Table 4 Minimum sample size required to obtain the desired power level 1-b for finding an effect when testing at a specific confidence level
1-a
a = 1-b = Constant I. Route of drug administration II. Effectiveness III. Nausea IV. Duration V. Costs
A B1 B2 B3 C D E F
0.1 0.6 2 28 72 13 2 1 17 3
0.05 0.6 3 43 111 19 2 1 27 4
0.025 0.6 4 58 151 26 3 2 36 6
0.01 0.6 6 79 205 35 5 3 49 8
0.1 0.7 3 39 100 17 2 1 24 4
0.05 0.7 4 56 145 25 3 2 35 6
0.025 0.7 6 73 190 33 4 3 46 7
0.01 0.7 7 96 250 43 6 3 60 10
0.1 0.8 4 53 139 24 3 2 33 5
0.05 0.8 6 73 190 33 4 3 46 7
0.025 0.8 7 93 241 42 5 3 58 9
0.01 0.8 9 119 308 53 7 4 74 12
0.1 0.9 6 78 202 35 5 3 49 8
0.05 0.9 8 102 263 45 6 4 64 10
0.025 0.9 10 125 323 56 7 4 78 13
0.01 0.9 12 154 400 69 9 5 97 16
Table 3 DCE design
Choice task Alternative Constant I. Route of drug administration II. Effectiveness III. Nausea IV. Duration V. Costs
A B1 B2 B3 C D E F
1 1 1 1 0 0 5 0 10 120
1 2 1 0 1 0 10 1 1 240
1 3 0 0 0 0 0 0 0 0
2 1 1 0 0 1 5 1 5 720
2 2 1 0 0 0 10 0 10 0
2 3 0 0 0 0 0 0 0 0
3 1 1 0 0 0 25 1 10 240
3 2 1 1 0 0 50 0 1 720
3 3 0 0 0 0 0 0 0 0
. . . . . . . . . .
. . . . . . . . . .
. . . . . . . . . .
16 1 1 0 1 0 10 0 10 720
16 2 1 0 0 1 25 1 1 0
16 3 0 0 0 0 0 0 0 0
alternative 1 = drug treatment alternative I; alternative 2 = drug treatment alternative II; alternative 3 = opt-out alternative; values 0 and 1 in
column A mean ‘opt-out alternative’ and ‘drug treatment alternative’, respectively; value 1 in columns B1, B2, B3 means ‘tablet every week’,
‘infusion every 4 months’, and ‘infusion every month’, respectively; column C presents how effective (risk reduction of a hip fracture in %) a
drug treatment alternative is; values 0 and 1 in column D mean ‘no nausea as a side effect’ and ‘nausea as a side effect’, respectively; column E
presents the total treatment duration in years; and the values in column F present the out-of-pocket costs (€)
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column B2). If a smaller sample size of, for
example, 111 respondents were to be used and
no significant result to be found for this
parameter, one has a statistical power of 0.6,
assuming an a = 0.05, to conclude that respon-
dents do not prefer ‘tablet every month’ over
‘injection every 4 months’. As a proof of
principle, we compared the standard errors
and confidence intervals from the actual study
[12] against the predicted standard errors and
confidence intervals. The results showed that
they were quite similar (Table 5), which gives
further evidence that our sample size calcula-
tion makes sense.
5 Discussion
In this paper, we have summarized how researchers have
dealt with sample size calculations for health care-related
DCE studies. We found that more than 70 % of the health
care-related DCE studies published in 2012 did not
(clearly) report whether and what kind of sample size
method was used. Just 6 % of the health care-related DCE
studies published in 2012 used a parametric approach for
sample size estimation. Nevertheless, the parametric ap-
proaches used were not suitable as a power calculation for
determining the minimum required sample size for hy-
pothesis testing for coefficients based on DCEs. To fill in
this gap, we explained the analysis needed to determine the
required sample size in DCEs from a hypothesis testing
perspective. That is, we clarified that the following five
elements are needed before such a minimum sample size
can be determined: significance level (a), statistical power
level (1-b), statistical model used in the DCE analysis,
initial belief about the parameter values, and the DCE
design. An important feature of the resulting sample size
formula is that the required sample size tends to grow
exponentially. For example, when one wants a certain
power level to detect an effect that is 50 % smaller, the
required sample will be four times larger.
To build a bridge between theory and practice, we cre-
ated a generic R-code as a practical tool for researchers to
be able to determine the minimum required sample size for
coefficients in DCEs. We then illustrate step-by-step how
the sample size requirement can be obtained using our
R-code. Although the R-code presented in this paper is for
MNL only, the theory is also suitable for other choice
models, such as the nested logit, mixed logit, scaled-MNL,
or generalized-MNL.
Our approach for determining the minimum required
sample size for coefficients in DCEs can also be extended
to functions of parameters. For example, one might want to
know whether patients are willing to pay a specific amount
to increase effectiveness by 10 %. In order to test such a
hypothesis, confidence intervals for a willingness-to-pay
measure are needed. Once how these will be inferred from
the limiting distribution of the parameters [42] is deter-
mined, RWTP (instead of Rc) is known and the required
sample size can be computed.
From a practical point of view, in health care-related
DCEs, the number of patients and physicians that can be
approached is often given, and sometimes rather small.
Especially in these cases, our tool could indicate that power
will be low. Using efficient designs (striving for small
values for
P
ck), more alternatives per choice set, or clear
Table 5 Parameter estimates and precision from an actual discrete-choice experiment study [12] relative to those predicted by the sample size
calculations
Attribute MNL results actual study (N = 117)a Predicted results based on 117 subjects
Parameter value SE 95 % CI SE 95 % CI
Constant (drug treatment) 1.23 0.218 0.81–1.66 0.109 1.02–1.45
Drug administration (base level tablet once a month):
Tablet once a week –0.31 0.070 -0.45 to -0.17 0.099 –0.50 to –0.12
Injection every 4 months –0.21 0.097 -0.41 to -0.02 0.108 –0.43 to –0.01
Injection once a month –0.44 0.100 -0.64 to -0.25 0.094 –0.63 to –0.26
Effectiveness (1 % risk reduction) 0.03 0.003 0.02–0.03 0.002 0.02–0.03
Side effect nausea –1.10 0.104 -1.30 to -0.89 0.065 –1.22 to –0.97
Treatment duration (1 year) –0.04 0.010 -0.06 to -0.02 0.010 –0.06 to –0.02
Cost (€1) –0.0015 0.0002 -0.002 to -0.001 0.0002 –0.002 to –0.001
CI confidence interval, SE standard error
a Number of observations 5589 (117 respondents 9 16 choices 9 3 options per choice, minus 27 missing values), Pseudo R2 = 0.185, log
pseudolikelihood = -1668.7
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wording and layout are ways to increase the power that is
achieved.
The approach presented in this paper can also be used to
reverse engineer the power that a specific design has for a
given sample size. This can help researchers who find an
insignificant result to ensure that they had sufficient power
to detect a reasonably sized effect.
6 Conclusion
The use of sample size calculations for healthcare-related
DCE studies is largely lacking. We have shown how
sample size calculations can be conducted for DCEs when
researchers are interested in testing whether a particular
attribute (level) affects the choices that patients or physi-
cians make. Such sample size calculations should be
executed far more often than is currently the case in
healthcare, as under-powered studies may lead to false
insights and incorrect decisions for policy makers.
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